Hepatitis B and C in Acute Lymphoblastic Leukemia

Sahib, Sura Salih; Jadiry, Mazin F.Al-

doi:10.52573/ipmj.2024.182889

	Hepatitis B and C in Acute Lymphoblastic Leukemia
Iraqi Postgraduate Medical Journal
Article 11, Volume 23, Issue 2, April 2024, Pages 191-196 PDF (260.55 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2024.182889
Authors
Sura Salih Sahib^* ¹; Mazin F.Al- Jadiry²
¹AL-Karkh Maternity Hospital, Baghdad, Iraq
²Children Welfare Teaching Hospital, Baghdad, Iraq
Abstract
BACKGROUND: The risk of acquiring both hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in patients with cancer has been documented. Risk of parenteral transmission of viral hepatitis has been well recognized, especially due to blood product transfusions. PATIENTS AND METHODS: The duration of the data collection and analysis of the study was from August 2018 till October 2019. A retrospective study included 92 children with Acute Lymphoblastic Leukemia diagnosed consecutively in a 2-year period; 2015-2016 at Oncology Unit in Children Welfare Teaching Hospital. Demographic information, treatment details, vaccination history and baseline hepatitis screen were documented. Follow up data during ALL therapy regarding the mass of blood products received by the patients, RESULTS: At the time of diagnosis, all patients were serologically negative from HBV and HCV. During the follow up period, there were 19 (20.6%) patients infected with hepatitis by serological method; 18 with hepatitis C and one with hepatitis B. there was no significant correlation between seroconversion with hepatitis and liver dysfunction, blood product transfusions more than 10 times, chemotherapy delay due to liver dysfunction and risk group. The mean duration from date of diagnosis till date of last follow up was 43.7 months (range 28.6-56.2 months), while the duration from date of diagnosis till seroconversion with hepatitis was 44.2 months (range 6.9-56.4 months). CONCLUSION: Low incidence of HBV and high incidence of HCV noticed in this group of patients, there is no direct significant correlation to blood product transfusions.
Keywords
ALL acute lymphoplastic leukemia; hepatitis b and c
Supplementary Files 10.pdf
References
Moicke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;1114477–89. Liu CJ, Chen PJ, Chen DS and Kao JH: Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2013; 7: 316 -26. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43:209- Ayyub M, El-Moursy SA, Al-Abbas Outcome of combination antiviral therapy in chronic hepatitis C virus infection during therapy of acute lymphoblastic leukemia. Saudi J Gastroenterol 2011;17:283–86. Torres HA, McDonald GB. How I treat hepatitis C virus infection in patients with hematologic malignancies. Blood 2016; 128:1449–57. Burton A, Monasch R, Lautenbach B, Gacic-Dobo M, Neill M, Karimov R, Wolfson L, Jones G, Birmingham M. WHO and UNICEF estimates of national infant immunization coverage: methods and processes. Bulletin of the World Health Organization. 2009;87:535-41. Al Jadiry MF, Al Khafagi M, Al Darraji AF, Al Saeed RM, Al Badri SF, Al Hadad SA. High incidence of hepatitis B infection after treatment for paediatric cancer at a teaching hospital in Baghdad, 2013. Mostafa A, Ebeid E, Mansour TA, Amin MA, Sidhom I, Khaeiry A, El-Zomer H. Seroprevalence of hepatitis B and C in pediatric malignancies. Journal of the Egyptian National Cancer Institute. 2003;15:33-42. Fujii X, Kaku K, Tanaka M, et al. Hepatitis C virus infection in patients with leukemia. Am J Hematol 1994;46:278-82.
Statistics Article View: 317 PDF Download: 90